Literature DB >> 9336875

Hypercholesterolemia as a risk factor for deep-vein thrombosis.

T Kawasaki1, J Kambayashi, H Ariyoshi, M Sakon, E Suehisa, M Monden.   

Abstract

Our retrospective study has shown that hyperlipidemia is a novel etiologic factor in deep-vein thrombosis (DVT) and that most of the idiopathic DVT patients were hyperlipidemic (Thrombosis Research 79, 147-151, 1995). The aim of our current study is to analyze the interrelationship between hyperlipidemia and DVT by means of a case-control study. A series of lipid parameters were analyzed using serum from 109 patients with deep vein thrombosis (DVT). One hundred nine age- and sex-matched subjects served as controls. Diagnosis of hyperlipidemia was made if the serum cholesterol level was above 220 mg/dL or if the triglyceride level was above 150 mg/dL. Among several types of hyperlipidemia examined, the risk factor associated with the highest estimated odds ratio was carriage of hypercholesterolemia associated with hypertriglyceridemia (odds ratio 5.1) followed in order by hypercholesterolemia without hypertriglyceridemia (odds ratio 2.6) and hypertriglyceridemia without hypercholesterolemia (odds ratio 0.9). These findings support the hypothesis that hypercholesterolemia plays an important role in the pathogenesis of DVT.

Entities:  

Mesh:

Year:  1997        PMID: 9336875     DOI: 10.1016/s0049-3848(97)00192-8

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  19 in total

1.  Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia.

Authors:  Yi Ma; Mohammad Z Ashraf; Eugene A Podrez
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

2.  Dyslipidaemia in Behcet's disease as a thrombotic risk factor.

Authors:  J M Ricart; A Vayá; M Santaolaria; F España; J Aznar
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

3.  Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study.

Authors:  Aneel A Ashrani; Michel K Barsoum; Daniel J Crusan; Tanya M Petterson; Kent R Bailey; John A Heit
Journal:  Thromb Res       Date:  2015-04-11       Impact factor: 3.944

4.  Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner.

Authors:  Kristina Sundquist; Abrar Ahmad; Peter J Svensson; Bengt Zöller; Jan Sundquist; Ashfaque A Memon
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

5.  Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease.

Authors:  M Leiba; U Seligsohn; Y Sidi; D Harats; B A Sela; J H Griffin; A Livneh; N Rosenberg; I Gelernter; H Gur; M Ehrenfeld
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

6.  High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.

Authors:  J H Griffin; K Kojima; C L Banka; L K Curtiss; J A Fernández
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

7.  The role of dyslipidemia and statins in venous thromboembolism.

Authors:  Joel G Ray; Frits R Rosendaal
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

8.  Influence of lipid metabolism disorders on venous thrombosis risk.

Authors:  Igor Spasić; Milan Ubavić; Zorica Šumarac; Maša Todorović; Biljana Vučković
Journal:  J Med Biochem       Date:  2021-06-05       Impact factor: 3.402

9.  Vascular Complications in Pediatric Pancreatitis: A Case Series.

Authors:  Chinenye R Dike; Gretchen Cress; Douglas S Fishman; Tanja Gonska; Chee Y Ooi; Emily R Perito; David Troendle; Cynthia M Tsai; Mark E Lowe; Aliye Uc
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-10-01       Impact factor: 3.288

Review 10.  Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis.

Authors:  Yun-Jiu Cheng; Zhi-Hao Liu; Feng-Juan Yao; Wu-Tao Zeng; Dong-Dan Zheng; Yu-Gang Dong; Su-Hua Wu
Journal:  PLoS Med       Date:  2013-09-17       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.